Antabio’s CEO Marc Lemonnier has been elected at the Board of Directors of the BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) further to the alliance’s Extraordinary General Assembly held in Paris on 20 December 2016.
The BEAM Alliance represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance. BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe.
The Board of Directors of the BEAM Alliance is elected for a period of three years and will be responsible for overall policy and direction of the Alliance in support of its mission to improve the regulatory, investment, and commercial environments in Europe for research, development, approval and market viability of new products combating antimicrobial resistance.
